CAR T Cells: Second-Line Treatment Option for NHL? - NCI
Dr. Leslie on the Methods of the ZUMA-7 Trial in Relapsed/Refractory LBCL
CAR-T 'highly cost-effective' as second-line treatment for large B-cell lymphoma
ZUMA-7 - Capsule Summary Slidesets - Lymphomas and CLL - 2021 ASH Annual Meeting - Oncology - Clinical Care Options
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma | Business Wire
Patient journey from screening to CAR T-cell infusion for JULIET and... | Download Scientific Diagram
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial - The Lancet Oncology
Kite's CAR-T Therapy Positions For First-In-Class To Treat Lymphoma (NASDAQ:KITE) | Seeking Alpha
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma | Business Wire
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma | BioSpace
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium | Journal of Clinical Oncology
CAR-T plus atezolizumab safe, effective in refractory diffuse large B-cell lymphoma
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials - Westin - 2021 - American Journal of Hematology -
ZUMA-7 Data Underscore Potential of CAR T-cell Therapy as Second-Line Standard in Relapsed/Refractory LBCL
ZUMA-7 trial shows superiority of CAR-T cell therapy for relapsed or refractory large B-cell lymphoma - Oncology Central
Clinical Review Results - Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report - NCBI Bookshelf
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma - ScienceDirect
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
ZUMA-7 Trial Meets Event-Free Survival End Point in Large B-Cell Lymphoma
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma | NEJM
